Lexicon Pharmaceuticals Shares Plunge On Proposed Public Offering

July 27, 2022 5:42 PM | 1 min read |

Lexicon Pharmaceuticals, Inc. LXRX shares dropped 18% in the after-hours session on commencing an underwritten public offering to offer and sell shares of its common stock, par value of $0.001.
Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock.
The financial terms and quantum of the offering were not disclosed.
LXRX intends to use the net proceeds for funding pre-commercial and commercial launch activities for sotagliflozin in heart failure; funding continued development of sotagliflozin in heart failure, and LX9211 in neuropathic pain; and working capital and other general corporate purposes.
Price Action: LXRX shares are trading lower by 18.96% at $2.65 during the post-market session on Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.